According to BIO President and CEO Jim Greenwood, patents are the lifeblood of innovative, lifesaving biotech companies. Hedge fund manager Kyle Bass has opened a new door to abuse of the US patent system, exploiting USPTO's patent challenge proceeding as part of his cynical short-selling strategy against innovative biotech companies that are delivering transformative therapies to patients in need. Congress and the USPTO should act promptly to prevent abuse of the patent system in this manner.